Key Milestones | MEDEZE Investor Relation (MEDEZE)

2024

21^st March 2024, the 2024 Annual General Meeting of Shareholders resolved to approve the Group to proceed as follows:
- Increase the registered capital of common shares by 134,000,000 Baht at a par value of 0.50 Baht per share, totaling 268,000,000 shares, resulting in an increase of the registered capital from 400,000,000 Baht to 534,000,000 Baht. The allocation of the Group’s newly issued common shares shall not exceed 268,000,000 shares for offering to the general public for the first time (IPO), and the meeting approved the listing of the Group’s common shares on the Stock Exchange of Thailand (“SET”).
- Currently, the Group has a total of 4 buildings used for its operations, comprising 1 head office building, 1 cell storage facility, 1 research and development building, and 1 Sales & Marketing building.
- The Group has initiated renovations to the research and development building, including construction and preparation of cleanroom laboratories for the installation of a Robotic Cell Culture System, which is currently under renovation within the existing building.
- The Board of Directors’ Meeting No. 5/2024 held on August 13, 2024, approved an interim dividend payment from retained earnings to existing shareholders prior to the Initial Public Offering (IPO) at the rate of 0.31 Baht per share, totaling 248 million Baht, based on the Company’s financial statements as of March 31, 2024.
- Received the Industry Champions of the Year award from ACES Awards 2024
- Received the Southeast Asia Stem Cell Banking Company of the Year award from Frost & Sullivan 2024

2023

8^th September 2023, the Extraordinary General Meeting of Shareholders No. 1/2023 passed special resolutions to approve the following key matters:
- Reduction of the Company’s registered capital by THB 75,000,000, equivalent to a reduction of 150,000,000 common shares at a par value of THB 0.50 per share, from the original registered capital of THB 300,000,000 to THB 225,000,000.
- Increase of the Company’s registered capital by THB 175,000,000, equivalent to an increase of 350,000,000 common shares at a par value of THB 0.50 per share, from the previous registered capital of THB 225,000,000 to a new registered capital of THB 400,000,000. The meeting also approved the allocation of the newly issued shares to existing shareholders in proportion to their shareholding. The Company has received full payment for the capital increase.
- The Company was awarded the Southeast Asia Stem Cell Banking Company of the Year 2023 by Frost & Sullivan.

2022

July 19, 2022: At the Extraordinary General Meeting of Shareholders No. 1/2022, the group approved the following actions:
- Conversion to a Public Company
  The group transformed into a public company under the name Medeze Group Public Company Limited. This transformation was officially registered on July 27, 2022, to prepare for listing on the Stock Exchange of Thailand (SET).
- Change in Par Value of Shares
  The par value of common shares was reduced from 100.00 Baht per share to 0.50 Baht per share. This adjustment increased the number of registered and issued shares from 450,000,000 to 600,000,000 shares, while the registered and paid-up capital remained unchanged. The change was officially registered with the Ministry of Commerce on July 27, 2022.
- Increase in Registered Capital
  An additional 75,000,000 Baht in registered capital was approved, at a par value of 0.50 Baht per share, resulting in the issuance of 150,000,000 new shares. This raised the registered capital from 225,000,000 Baht to 300,000,000 Baht. These additional shares were allocated for the group’s initial public offering (IPO). More details can be found in Section 4, “Information Regarding the Offering of Securities.”
- Approval for SET Listing
  The common shares of the group were approved for listing on the Stock Exchange of Thailand (SET).

2021

April 27, 2021: The Annual General Meeting of Shareholders for 2021 approved an increase in registered capital to 203,000,000 Baht. This was achieved by issuing 180,000 additional shares with a par value of 100 Baht per share. The capital increase was intended to support business growth. The registration of the capital increase with the Ministry of Commerce was completed on May 6, 2021.
September 2, 2021: The Extraordinary General Meeting of Shareholders No. 1/2021 approved an increase in registered capital to 225,000,000 Baht. This was done by issuing 220,000 additional shares with a par value of 100 Baht per share. The purpose of the capital increase was to prepare for listing on the Stock Exchange of Thailand (SET). The registration of the capital increase with the Ministry of Commerce was completed on September 15, 2021.
The meeting also approved a dividend payment of 20.00 Baht per share from the group’s retained earnings, totaling 40.60 million Baht in dividends distributed to shareholders.
Establishment of Subsidiaries: Medeze NK Co., Ltd.: Established with a registered capital of 20,000,000 Baht, supported by the Board of Investment (BOI) for the purpose of testing the potential of immune cells (NK Cells).
Medeze Treasury Pte. Ltd. (Singapore): Established with a registered capital of 1,820,000 Singapore dollars as an investment arm.
Medeze Group Pte. Ltd. (Singapore): Established with a registered capital of 2,400,000 Singapore dollars to conduct experimental research in natural sciences and operate medical laboratories.
Awards Received in 2021: Thailand Stem Cell Banking Company of the Year Award from Frost & Sullivan.
Southeast Asia Banking Company of the Year Award from Frost & Sullivan.

2020

December 15, 2020: The Extraordinary General Meeting of Shareholders No. 2/2020 approved an increase in the company’s registered capital to 185,000,000 Baht. This was achieved by issuing 590,000 additional shares with a par value of 100 Baht per share. The capital increase was aimed at supporting business growth. The registration of the capital increase with the Ministry of Commerce was completed on December 22, 2020.
Awards Received in 2020: Southeast Asia Stem Cell Banking Technology Innovation Leadership Award from Frost & Sullivan.
Thailand Stem Cell Banking Company of the Year Award from Frost & Sullivan.

2019

Implementation of Advanced Technology: Began utilizing an automated mesenchymal stem cell expansion system (Quantum) to cultivate and expand stem cells from tissue within a short period.
AABB Accreditation: Received accreditation from the Association for the Advancement of Blood and Biotherapies (AABB) in the United States, recognizing the company’s compliance with rigorous operational standards for stem cell banking.
Awards Received in 2019: Southeast Asia Stem Cell Banking Growth Excellence Leadership Award from Frost & Sullivan.
Thailand Stem Cell Banking Company of the Year Award from Frost & Sullivan.
Thailand Brand Leadership Award from CMO Asia

2018

December 6, 2018: The Extraordinary General Meeting of Shareholders No. 2/2018 approved an increase in the company’s registered capital to 150,000,000 Baht. This was achieved by issuing 300,000 additional shares with a par value of 100 Baht per share. The capital increase was aimed at supporting business growth and was duly registered with the Ministry of Commerce.
Launch of the Medeze Application: Introduced the Medeze mobile application to provide customers with convenient access to information about their stem cell storage services.
Company Name Change: Changed the company’s name from Bangkok Stem Cell Co., Ltd. to Medeze Group Co., Ltd.
Awards Received in 2018: Thailand Stem Cell Banking Company of the Year Award from Frost & Sullivan.

2017

December 22, 2017: The Extraordinary General Meeting of Shareholders No. 2/2017 approved an increase in the company’s registered capital to 120,000,000 Baht. This was achieved by issuing 700,000 additional shares with a par value of 100 Baht per share. The capital increase supported business growth and was duly registered with the Ministry of Commerce.
Launch of Immune Cell (NK Cells) Testing Services: The company began offering services to test the potential of immune cells (NK Cells).
ISO 22716:2007 Certification: The company received the ISO 22716:2007 certification from MS Certification Services Pvt. Ltd.
Awards Received in 2017: Thailand Stem Cell Banking Growth Excellence Leadership Award from Frost & Sullivan.
Thailand Stem Cell Banking Company of the Year Award from Frost & Sullivan.

2016

September 15, 2016: The Extraordinary General Meeting of Shareholders No. 3/2016 approved an increase in the company’s registered capital to 50,000,000 Baht. This was achieved by issuing 200,000 additional shares with a par value of 100 Baht per share. The capital increase was aimed at supporting business growth and was duly registered with the Ministry of Commerce.
Establishment of Subsidiaries: Medeze Cosmeceuticals Co., Ltd.: Established with a registered capital of 1,000,000 Baht to engage in the sale of beauty products.
Medeze Research and Development Co., Ltd.: Established with a registered capital of 7,500,000 Baht to conduct experimental research and development in biotechnology.

2015

October 1, 2015: The Extraordinary General Meeting of Shareholders No. 1/2015 approved an increase in the company’s registered capital to 30,000,000 Baht. This was achieved by issuing 100,000 additional shares with a par value of 100 Baht per share. The capital increase was aimed at supporting business growth and was duly registered with the Ministry of Commerce.

2013

June 26, 2013: The Extraordinary General Meeting of Shareholders No. 1/2013 approved an increase in the company’s registered capital to 20,000,000 Baht. This was achieved by issuing 170,000 additional shares with a par value of 100 Baht per share. The capital increase was aimed at supporting business growth and was duly registered with the Ministry of Commerce.
ISO 9001:2008 Certification: The company received the ISO 9001:2008 certification, recognizing its commitment to quality management standards.
Launch of Stem Cell Storage Services: The company began offering stem cell storage services using tissue extracted from the fat of individuals for stem cell banking.

2011

Implementation of Automated Sorting Technology: The company began using the AutoXpress automated machine, which can separate hematopoietic stem cells from umbilical cord blood. This technology reduces the risk of contamination and human error during the stem cell separation process.

2010

July 19, 2010: The company was officially registered under the name Bangkok Stem Cell Co., Ltd., with a registered capital of 3,000,000 Baht, divided into 30,000 shares with a par value of 100 Baht per share. The founding shareholders were Dr. Weerapol Khemarungsan, Associate Professor Dr. Rangsak Phalapai, and Dr. Jamras Sukulpaisal, with ownership distributions as follows: Dr. Weerapol Khemarungsan (50%), Mrs. Kittima Khemarungsan (33.33%), and Dr. Jamras Sukulpaisal (16.67%). The company was established to provide services related to the analysis, separation, cultivation, and storage of stem cells.

A Leader in Sales and Innovation

in the stem cell banking and immunotherapy technology industry,

Backed by awards and continuous business growth spanning over 11 years.